Immutrin
Recent Finacing
Series A
Recent Raise
$87.2M
Immutrin is a biotechnology company developing next-generation antibody therapies to deplete systemic amyloid deposits and reverse amyloidosis.
Highlights
Focus Areas
Biotechnology
Recent Investors
Financials
$87.2M
Total Raised
1
Funding round